David Liew drdavidliew
5 years 11 months ago
COVID-19 changes everything, but our vasculitis patients particularly have had some really difficult decisions to make.
@VasculitisFound @michaelgeorgemd @maferradastrong @petercgrayson @RADoctor @DrPeterMerkel et al
#ACR20 ABST1416 @RheumNow https://t.co/lWXtgSqDqy
Dr. Antoni Chan synovialjoints
5 years 11 months ago
Exploring new mode of action for treatment of AS. In BE AGILE study, Bimekizumab (BKZ) provides further sustained long-term improvements post 48 weeks in key efficacy outcome measures to 96 weeks of treatment @RheumNow #ACR20 Abstr#1364 https://t.co/972AvDNJDq
Dr. John Cush RheumNow
5 years 11 months ago
Interim analysis of the RELIANCE registry studying effect of canakinumab (CAN) in 80 patients w/ febrile CAPS. Efficacy of CAN assessed w/ AIDA (inflam index) showing ~70% were in low activity (<9) @ACR20 Abstr#1479 https://t.co/UC2eJbpVLM https://t.co/M71s8gXZY9
David Liew drdavidliew
5 years 11 months ago
In the current era, would a positive treat-to-target study in AS change your approach to practice?
(TICOSPA trial ABST1444) #ACR20 @RheumNow
Dr. Rachel Tate uptoTate
5 years 11 months ago
Wanna learn about T2T PsA abstracts from #ACR20? Here are my highlights! @RheumNow https://t.co/0X7FF3rwTz
Dr. Rachel Tate uptoTate
5 years 11 months ago
Check out my video on T2T in SpA abstracts from #ACR20 @RheumNow https://t.co/ZBvmhWyDHU
David Liew drdavidliew
5 years 11 months ago
We're getting better at treating vasculitis over time.
In-hospital mortality in pts primarily admitted with vasculitis is got much closer to all-comers 1998-2014 (US NIS). Hopefully with more new meds, we've closed the gap even more since!
@UABRheum #ACR20 ABST1423 @RheumNow https://t.co/kNq8HCjqQ0
Dr. Rachel Tate uptoTate
5 years 11 months ago
Dr. Crow's #StateoftheArt lecture revealed that BEL may be best used in pts with < 2 years and SLEDAI >10 based on the study from Gatto, M et al from 2020. Does this change how you will use BEL in your practice? #ACR20 @RheumNow
David Liew drdavidliew
5 years 11 months ago
Can hs-troponin and hsCRP predict future major cardiovascular events? Certainly appears so in RA pts (n=636).
To what extent do subclinical dx and inflammation combine to cause future RA CV pain?
PRECISION trial subgroup @ElaineHusniMD @DanielHSolomon #ACR20 ABST1189 @RheumNow https://t.co/ZYTpodatVI
Potpourri of Pathotypes of Predictors with RA Faculty
Dr. Jonathan Kay again leads an international panel of rheumatologists to elicit their opinions on key abstracts at ACR 2020. Panelists: Dr. David Liew, Dr. Eric Dein, Dr. Meral El Ramahi, Dr. Richard Conway, Dr. Sheila Reyes and Dr. Jeffrey Sparks.
Outpatient Billing and Coding Pearls: Dr Rachel Tate
Dr. Rachel Tate reviews outpatient billing and coding pearls presented at a session at the 2020 ACR annual meeting.
Dr. John Cush RheumNow
5 years 11 months ago
RheumNow’s expanded coverage of the annual #ACR2020 meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.
Robert B Chao, MD doctorRBC
5 years 11 months ago
SELECT-PsA Phase 3, Placebo, Active controlled trial of Upadacitinib in PsA
1⃣UPA 15mg or 30mg - ⬆️PROs vs. Placebo thru 24wks
2⃣Similar improvement in UPA 15mg vs. 30mg
3⃣Both doses similar or > Adalimumab
@RheumNow #ACR20 Abs#1341 #ACRbest https://t.co/yu9IEX8tf0
Check on Pneumococcal Vaccination: Dr. Janet Pope
Dr. Janet Pope reviews abstracts #0456 and #0457 presented at the 2020 ACR annual meeting.
David Liew drdavidliew
5 years 11 months ago
The lung-joint axis in RA just keeps on getting stronger
Lung ACPA present in early untreated RA/CSA:
crossreact acetylated/carbamylated antigens
differ in effects on cell types (neut activation, fibroblasts, osteoclasts)
Isn't lung ACPA fascinating?
#ACR20 ABST1445 @RheumNow https://t.co/9VKSRYlndT
